Anavex Life Sciences Presents New Data From Its Ad-004 Phase Iib/Iii Trial at Ad/Pd 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences Presents New Data From Its Ad-004 Phase Iib/Iii Trial at Ad/Pd 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Comments